IP Library Granted Patent US 9,890,148
Granted Patent B2
US 9,890,148 · App. 14/551,438 · Granted Feb 13, 2018

Aryl sulfonamides

Inventors: Solomon Ungashe (Fremont, CA); John J. Wright (Redwood City, CA); Andrew Pennell (San Francisco, CA); Zheng Wei (Union City, CA); Anita Melikian (Mountain View, CA)
Assignee: ChemoCentryx, Inc.
C07D417/12A61K31/443A61K31/4409A61K31/4439A61K31/4545A61K31/496A61K31/5377A61K31/541A61K45/06C07D213/26C07D213/50C07D213/52C07D213/70C07D213/74C07D213/84C07D213/89C07D239/26C07D241/12C07D401/12C07D405/12C07D409/12C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,148
App. No.
14/551,438
Granted
Feb 13, 2018
Kind
B2
Abstract

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Claims (22)

1. A compound of the formula (I), or a salt thereof:

where X represents from 1 to 4 substituents independently selected from the group consisting of halogen, —CN, —NO 2 , —OH, —OR 1 , —C(O)R 1 , —CO 2 R 1 , —O(CO)R 1 , —C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —SR 1 , —SOR 1 , —SO 2 R 1 , —SO 2 NR 1 R 2 , —NR 1 R 2 , —NR 1 C(O)R 2 , —NR 1 C(O) 2 R 2 , —NR 1 SO 2 R 2 , —NR 1 (CO)NR 2 R 3 , unsubstituted C 1-8 alkyl, unsubstituted C 2-8 alkenyl, and unsubstituted C 2-8 alkynyl,

R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, unsubstituted C 1-6 haloalkyl, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl,

or two of R 1 , R 2 and R 3 together with the atom(s) to which they are attached, may form an unsubstituted 5-, 6- or 7-membered ring;

Y represents from 1 to 3 substituents, each independently selected from the group consisting of halogen, —CN, —NO 2 , —OH, —OR 4 , —C(O)R 4 , —CO 2 R 4 , —SR 4 , —SOR 4 , —SO 2 R 4 , and unsubstituted C 1-4 alkyl;

R 4 is selected from the group consisting of hydrogen, unsubstituted C 1-6 haloalkyl, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl; L is —C(O)—, —S—, —SO— or —S(O) 2 ; and Z is an unsubstituted or substituted heteroaryl selected from indazolyl, pyrimidinyl, pyridazinyl, and pyrazinyl.

2. The compound of claim 1 , where L is —CO—.

3. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .

4. The compound of claim 1 , where the compound is selected from one of formulas XXI-XXVI

where X a and X b are independently selected from the group consisting of: hydrogen, halogen, —CN, —NO 2 , —OH, —OR 1 , —C(O)R 1 , —CO 2 R, —O(CO)R 1 , —C(O)NR 1 R 2 , —OC(O)NR 1 R 2 , —SR 1 , —SOR 1 , —SO 2 R 1 , —SO2NR 1 R 2 , —NR 1 R 2 , —NR 1 C(O)R 2 , —NR 1 C(O) 2 R 2 , —NR 1 SO 2 R 2 , —NR 1 (CO)NR 2 R 3 , unsubstituted C 1-8 alkyl, unsubstituted C 2-8 alkenyl, unsubstituted C 2-8 alkynyl, and unsubstituted C 3-8 cycloalkyl;

R 1 , R 2 and R 3 are each independently selected from the group consisting of hydrogen, unsubstituted C 1-6 haloalkyl, unsubstituted C 1-6 alkyl, unsubstituted C 2-5 alkenyl, and unsubstituted C 2-6 alkynyl; or

two of R 1 , R 2 and R 3 together with the atom(s) to which they are attached, may form an unsubstituted 5-, 6- or 7-membered ring; where Y a and Y b are independently selected from the group consisting of: hydrogen, halogen, —CN, —NO 2 , —OH, —OR 4 , —C(O)R 4 , —CO2R 4 , —SR 4 , —SOR 4 , —SO2R 4 , and unsubstituted C 1-4 alkyl;

R 4 is selected from the group consisting of hydrogen, unsubstituted C 1-6 haloalkyl, unsubstituted C 1-6 alkyl, unsubstituted C 3-6 cycloalkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

where Z a and Z b are independently selected from the group consisting of: hydrogen, halogen, unsubstituted C 1-8 alkyl, unsubstituted C 2-8 alkenyl, unsubstituted C 2-8 alkynyl, —CN, ═O, —NO 2 , —OR 10 , —OC(O)R 10 , —CO 2 R 10 , —C(O)R 10 , —C(O)NR 11 R 12 , —OC(O)NR 11 R 12 , —NR 10 C(O)R 11 , —NR 10 C(O)NR 11 R 12 , —NR 11 R 12 , —NR 10 CO 2 R 11 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —S(O) 2 NR 11 R 12 , and —NR 10 S(O) 2 R 11 ;

R 10 , R 11 and R 12 are each selected from hydrogen, C 1-8 alkyl, C 2-8 alkenyl, and C 2-8 alkynyl.

5. The compound of claim 4 , where the compound is of formula XXI.

6. The compound of claim 4 , where the compound is of formula XXII.

7. The compound of claim 4 , where the compound is of formula XXIII.

8. The compound of claim 4 , where the compound is of formula XXIV.

9. The compound of claim 4 , where the compound is of formula XXV.

10. The compound of claim 4 , where the compound is of formula XXVI.

11. A compound which is

Assignments (2)
ASSIGNEE CHANGE OF ADDRESS Recorded Jun 27, 2023
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 064144/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2017
From: UNGASHE, SOLOMON; WRIGHT, JOHN J.; PENNELL, ANDREW; WEI, ZHENG; MELIKIAN, ANITA
To: CHEMOCENTRYX, INC.
Reel/Frame 043586/0393 →
Continuity (7)
Continuation 13852167 · Mar 28, 2013
Continuation 13245568 · Sep 26, 2011
Continuation 12137006 · Jun 11, 2008
Continuation 10846241 · May 13, 2004
Continuation In Part 10716170 · Nov 17, 2003
Provisional Application 60427670 · Nov 18, 2002
Related Publication 20150080351A1 · Mar 19, 2015